Thymoma
Conditions
Brief summary
The purpose of this study is to determine whether radiotherapy (RT) combined with recombined human granulocyte-macrophage colony stimulating factor(rhGM-CSF) is safe, effective in the treatment of patients with advanced thymic epithelial tumours.
Interventions
RADIATIONRadiotherapy Combined with GM-CSF
Patients with stable or progressing metastatic thymic epithelial tumours, with at least two distinct measurable sites of disease, were treated with concurrent radiotherapy (35 Gy in ten fractions or 60Gy in 30 fractions) to one metastatic site and granulocyte-macrophage colony-stimulating factor (125 μg/m(2) subcutaneously injected daily for 2 weeks, starting during the second week of radiotherapy).
Sponsors
Shanghai Cancer Hospital, China
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Age ≥18 years; 2. Histologically proven thymic epithelial tumours； 3. Stage IV according to UICC stage system(version 8,2017), at least with two evaluable abscopal lesions (≥1cm)（excluding intestinal metastasis）; 4. Evaluated as effective or stable disease after first-line chemotherapy or progressed after second-line chemotherapy (progression sites were no more than three sites); 5. ECOG performance status: 0-1; 6. Life expectancy ≥ 3 months. 7. Adequate baseline organ and marrow function: absolute neutrophil count greater than 1500 cells per μL, platelet concentration of greater than 50 000 per μL, total bilirubin less than 1•5 times the upper limit of normal (ULN), aspartate aminotransferase and alanine aminotransferase less than 2•5 times the ULN, and serum creatinine less than 1•5 times the ULN; 8. Female subjects have a negative urine or serum pregnancy test within 1 week prior to treatment if of childbearing potential; 9. Asymptomatic subjects with brain metastasis can be included, but the sites of brain cannot be considered as target sites; 10. Asymptomatic subjects with bone metastasis can be included, but the sites of bone cannot be considered as target sites.
Exclusion criteria
1. Having received immunotherapy within 4 weeks prior to inclusion; 2. Allergic to GM-CSF, INF-α2b or diagnosed with immune system disease, receiving immunosuppressant, such as prednisone, dexamethasone, methylprednisolone, methotrexate, hydroxychloroquine, cyclophosphamide, azathioprine and so one; 3. Receiving treatment of other trials; 4. Any unstable systemic disease, including active infection, symptomatic congestive heart failure,myocardial infarction onset six months before included into the group, unstable angina, and severe arrhythmia, uncontrolled chronic lung disease; 5. Unwilling to sign consent; 6. Women in pregnancy or lactation;
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The abscopal effect rate | up to 12 months | The proportion of patients with an abscopal response assessed after the initiation of treatment The proportion of patients with an abscopal response assessed after the initiation of treatment |
Countries
China
Outcome results
None listed